BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cao M, Guilleminault C. Hypocretin and its emerging role as a target for treatment of sleep disorders. Curr Neurol Neurosci Rep 2011;11:227-34. [PMID: 21170610 DOI: 10.1007/s11910-010-0172-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Roecker AJ, Mercer SP, Schreier JD, Cox CD, Fraley ME, Steen JT, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. ChemMedChem 2014;9:311-22. [PMID: 24376006 DOI: 10.1002/cmdc.201300447] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
2 Tanaka S, Toyoda H, Honda Y, Seki Y, Sakurai T, Honda K, Kodama T. Hypocretin/orexin prevents recovery from sickness. Biomed Rep 2015;3:648-50. [PMID: 26405539 DOI: 10.3892/br.2015.491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
3 Kornum BR, Faraco J, Mignot E. Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain. Curr Opin Neurobiol 2011;21:897-903. [PMID: 21963829 DOI: 10.1016/j.conb.2011.09.003] [Cited by in Crossref: 88] [Cited by in F6Publishing: 76] [Article Influence: 8.0] [Reference Citation Analysis]
4 Nixon JP, Mavanji V, Butterick TA, Billington CJ, Kotz CM, Teske JA. Sleep disorders, obesity, and aging: the role of orexin. Ageing Res Rev 2015;20:63-73. [PMID: 25462194 DOI: 10.1016/j.arr.2014.11.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 7.6] [Reference Citation Analysis]
5 Black SW, Morairty SR, Fisher SP, Chen TM, Warrier DR, Kilduff TS. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep 2013;36:325-36. [PMID: 23449602 DOI: 10.5665/sleep.2442] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Dingemanse J, Hoever P. Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjects. Drugs R D 2013;13:145-51. [PMID: 23737453 DOI: 10.1007/s40268-013-0017-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
7 Roecker AJ, Reger TS, Mattern MC, Mercer SP, Bergman JM, Schreier JD, Cube RV, Cox CD, Li D, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett 2014;24:4884-90. [PMID: 25248679 DOI: 10.1016/j.bmcl.2014.08.041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
8 Joiner WJ. The Neurobiological Basis of Sleep and Sleep Disorders. Physiology (Bethesda) 2018;33:317-27. [PMID: 30109824 DOI: 10.1152/physiol.00013.2018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Thomasy HE, Opp MR. Hypocretin Mediates Sleep and Wake Disturbances in a Mouse Model of Traumatic Brain Injury. J Neurotrauma 2019;36:802-14. [PMID: 30136622 DOI: 10.1089/neu.2018.5810] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
10 Mahoney CE, Mochizuki T, Scammell TE. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice. Sleep 2020;43:zsz302. [PMID: 31830270 DOI: 10.1093/sleep/zsz302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
11 Black SW, Morairty SR, Fisher SP, Chen TM, Warrier DR, Kilduff TS. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep 2013;36:325-36. [PMID: 23449602 DOI: 10.5665/sleep.2442] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
12 Nollet M, Gaillard P, Tanti A, Girault V, Belzung C, Leman S. Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression. Neuropsychopharmacology 2012;37:2210-21. [PMID: 22713907 DOI: 10.1038/npp.2012.70] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 9.1] [Reference Citation Analysis]
13 Valiante S, Liguori G, Tafuri S, Campese R, Monaco R, Paino S, Laforgia V, Staiano N, Vittoria A. Expression of orexin A and its receptor 1 in the human prostate. J Anat 2013;222:473-80. [PMID: 23425077 DOI: 10.1111/joa.12030] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
14 Roecker AJ, Mercer SP, Harrell CM, Garson SL, Fox SV, Gotter AL, Prueksaritanont T, Cabalu TD, Cui D, Lemaire W, Winrow CJ, Renger JJ, Coleman PJ. Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis. Bioorganic & Medicinal Chemistry Letters 2014;24:2079-85. [DOI: 10.1016/j.bmcl.2014.03.052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
15 Roecker AJ, Mercer SP, Bergman JM, Gilbert KF, Kuduk SD, Harrell CM, Garson SL, Fox SV, Gotter AL, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Lemaire W, Winrow CJ, Renger JJ, Coleman PJ. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements. Bioorganic & Medicinal Chemistry Letters 2015;25:4992-9. [DOI: 10.1016/j.bmcl.2014.12.081] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
16 Kis GK, Molnár AH, Daruka L, Gardi J, Rákosi K, László F, László FA, Varga C. The osmotically and histamine-induced enhancement of the plasma vasopressin level is diminished by intracerebroventricularly administered orexin in rats. Pflugers Arch - Eur J Physiol 2012;463:531-6. [DOI: 10.1007/s00424-012-1080-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
17 Strambi LF. A need for new treatments in narcolepsy. The Lancet Neurology 2013;12:1039-40. [DOI: 10.1016/s1474-4422(13)70178-9] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
18 Shankar A, Williams CT. The darkness and the light: diurnal rodent models for seasonal affective disorder. Dis Model Mech 2021;14:dmm047217. [PMID: 33735098 DOI: 10.1242/dmm.047217] [Reference Citation Analysis]
19 Leak RK, Moore RY. Innervation of ventricular and periventricular brain compartments. Brain Res 2012;1463:51-62. [PMID: 22575559 DOI: 10.1016/j.brainres.2012.04.055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]